(Q33596889)

English

Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

Is severe depression a separate indication? ECNP Consensus Meeting September 20, 1996, Amsterdam. European College of Neuropsychopharmacology (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

Montgomery SA

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lecrubier Y

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

European Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

259-264

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of moclobemide in different patient groups: a meta-analysis of studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of tricyclic antidepressant response: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nortriptyline in depressed patients with high plasma levels. II

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels: a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Milnacipran and selective serotonin reuptake inhibitors in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The advantages of paroxetine in different subgroups of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Moclobemide in the treatment of social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Severity of depression and response to fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2898%2900048-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0924-977X(98)00048-0

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33596889&oldid=1706644262"